Longevica Therapeutics

Longevica Therapeutics is a preclinical biotechnology company pioneering target discovery and small-molecule therapeutics from full-lifespan mammalian geroscience. The company's foundation is built on a landmark four-year, $13 million in vivo mammalian screening program conducted at The Jackson Laboratory, which systematically evaluated 1,033 small-molecule compounds across more than 16,000 mouse subjects over their natural lifespans. This program generated a proprietary dataset characterized as the world's largest mammalian longevity screening program of its kind. Longevica is currently focused on converting this full-lifespan empirical data into defined biological mechanisms, druggable targets, and therapeutic development programs. The company aims to advance selected candidates into formal IND-enabling studies for high-unmet-need age-related disorders.